PRIME designation granted by European Medicines Agency for Roche's risdiplam for treatment of spinal muscular atrophy (SMA) Risdiplam has the potential to be the first oral medicine for the treatment of SMA - Types 1, 2 and 3; a rare and debilitating genetic disease most commonly diagnosed in chi

At three years, 88.3% of people treated with Kadcyla in the adjuvant HER2-positive early breast cancer setting did not have their breast cancer return compared to 77.0% treated with Herceptin, an 11.3% improvement People who have residual disease after neoadjuvant treatment h

New analyses from the phase III MURANO study in previously treated chronic lymphocytic leukaemia show continued benefit from fixed-duration regimen after a median follow-up of three years Updated results from two studies in newly-diagnosed acute myeloid leukaemia demonstrate Venclexta combination

Approval based on survival benefit of Tecentriq in combination with Avastin, paclitaxel and carboplatin (chemotherapy) in people with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumour aberrations compared to Avastin plus chemotherapy Roche today announc

Roche today announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) treatment of people with extensive-stage small cell lung cancer (ES - SCLC).

Nearly 77% of children receiving Hemlibra once weekly experienced zero treated bleeds Hemlibra once weekly reduced treated bleeds by 99% compared to prior bypassing agents in a prospective intra-patient comparison Hemlibra every two weeks and every four weeks also showed clinically meaningful con